Stephan Polterauer

Associate Professor / MD

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria Professors in Cancer Biology Cancer Biology professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Stephan Polterauer is an Associate Professor at the Medical University of Vienna, Austria. His research primarily focuses on advanced ovarian cancer, particularly in assessing postoperative residual disease using ctDNA, as well as exploring novel targeted therapies for chemoresistant diseases. He has published extensively on surgical outcomes in cancers such as cervical and uterine carcinosarcoma, and the prognostic value of various clinical indices in cancer treatment.

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Heini Lassus

University of Helsinki

FINLAND

View details

Leonhard Müllauer

Pathologist/Molecular Pathologist/Associate Professor

Medical University of Vienna

AUSTRIA

View details

Christoph Grimm

Medical University of Vienna

AUSTRIA

View details

Sakari Hietanen

Chief of Dept.

Helsinki University Hospital

FINLAND

View details

Tim Dorittke

Medical University of Vienna

AUSTRIA

View details

Ignacio Zapardiel

La Paz University Hospital

SPAIN

View details

Renaud Sabatier

Associate Professor

Aix-Marseille Université Faculté de Medecine

FRANCE

View details

Kinga Chalubinski

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephan Polterauer

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

Oncologic and Obstetric Outcomes Following Radical Abdominal Trachelectomy in Non-Low-Risk Early-Stage Cervical Cancers: A 10-Year Austrian Single-Center Experience

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

The Predictive Value of the Fibrinogen–Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer

Krukenberg Progression of Gastric Carcinoma in Pregnancy: Is Early Diagnosis Possible? Case Report and Review of the Literature

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)

Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival

The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients

Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study ( <scp>RESPONSE</scp> trial)

Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters

Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer

Collaborators (8)

Heini Lassus

Leonhard Müllauer

Christoph Grimm

Sakari Hietanen

Tim Dorittke

Ignacio Zapardiel

Renaud Sabatier

Kinga Chalubinski

Make your next move.